Suppression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection

Cancer Research

Volumn 59, Issue 15, 1999, Pages 3552-3556

  Luo, Jun ^a   Lubaroff, David M ^a   Hendrix, Mary J C ^a,b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE; UVOMORULIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INVASION; ENZYME ACTIVITY; GENETIC TRANSFECTION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN EXPRESSION; RAT;

ADENOCARCINOMA; ANIMALS; CADHERINS; ENZYME INDUCTION; GELATINASES; MALE; MATRIX METALLOPROTEINASE 2; METALLOENDOPEPTIDASES; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PHENOTYPE; PROSTATIC NEOPLASMS; RATS; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033178761     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Stetler-Stevenson, W. G., Aznavoorian, S., and Liotta, L. A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell Biol., 9: 541-573, 1993.
2. Bracke, M. E., Van Roy, F. M., and Mareel, M. M. The E-cadherin/catenin complex in invasion and metastasis. Curr. Top. Microbiol. Immunol., 213: 123-161, 1996.
3. Kemler, R. From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet., 9: 317-321, 1993.
4. Smith, M. E. F., and Pignatelli, M. The molecular histology of neoplasia: the role of the cadherin/catenin complex. Histopathology, 31: 107-111, 1997.
5. Paul, R., Ewing, C. M., Jarrard, D. F., and Isaacs, W. B. The cadherin cell-cell adhesion pathway in prostate cancer progression. Br. J. Urol., 79(Suppl. 1): 37-43, 1997.
6. Graff, J. R., Herman, J. G., and Lapidus, R. G. E-Cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res., 55: 5195-5199, 1995.
7. Ewing, C. M., Ru, N., Morton, R. A., Robinson, J. C., Wheelock, M. J., Johnson, K. R., Barrett, J. C., and Isaacs, W. B. Chromosome 5 suppresses tumorigenicity of PC-3 prostate cancer cells: correlation with re-expression of α-catenin and restoration of E-cadherin function. Cancer Res., 55: 4813-4817, 1995.
8. Richmond, P. J., Karayiannakis, A. J., Nagafuchi, A., Kaisary, A. V., and Pignatelli, M. Aberrant E-cadherin and α-catenin expression in prostate cancer: correlation with patient survival. Cancer Res., 57: 3189-3193, 1997.
9. Umbas, R., Isaacs, W. B., Bringuier, P. P., Xue, Y., Debruyne, F. M., and Schalken, J. A. Relation between aberrant α-catenin expression and loss of E-cadherin function in prostate cancer. Int. J. Cancer, 74: 374-377, 1997.
10. Bussemakers, M. J. G., Moorselaar, R. J. A., Giroldi, L. A., Ichikawa, T., Isaacs, J. T., Takeichi, M., Debruyne, F. M., and Schalken, J. A. Decreased expression of E-cadherin in the progression of rat prostate cancer. Cancer Res., 52: 2916-2922, 1992.
11. Umbas, R., Isaacs, W. B., Bringuier, P. P., Schaafsma, H. E., Karthaus, H. F., Oosterhof, G. O., Debruyne, F. M., and Schalken, J. A. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res., 54: 3923-3933, 1994.
12. Cheng, L., Nagabhushan, M., Pretlow, T. P., Amini, S. B., and Pretlow, T. G. Expression of E-cadherin in primary and metastatic prostate cancer. Am. J. Pathol., 148: 1375-1380, 1996.
13. Luo, J., Sharma, N., Seftor, E. A., DeLarco, J., Heidger, P. M., Hendrix, M. J. C., and Lubaroff, D. M. Heterogeneous expression of invasive and metastatic properties in a prostate tumor model. Pathol. Oncol. Res., 3: 264-271, 1997.
14. Nagafuchi, A., Shirayoshi, Y., Okazaki, K., Yasuda, K., and Takeichi, M. Transformation of cell adhesion properties by exogenously introduced E-cadheirn cDNA. Nature (Lond.), 329: 341-343, 1987.
15. Hendrix, M. J. C., Seftor, E. A., Seftor, R. E. B., and Fidler, I. J. A simple quantitative assay for studying the invasive potential of high and low metastatic variants. Cancer Lett., 38: 137-147, 1987.
16. 3 integrin in human melanoma cell invasion. Proc. Natl. Acad. Sci. USA, 89: 1557-1561, 1992.
17. Papkoff, J. Regulation of complexed and free catenin pools by distinct mechanisms. Differential effects of Wnt-1 and v-Src. J. Biol. Chem., 272: 4536-4543, 1997.
18. Stearns, M., and Stearns, M. E. Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncol. Res., 8: 69-75, 1996.
19. Gohji, K., Fujimoto, N., Hara, I., Fujii, A., Gotoh, A., Okada, H., Arakawa, S., Kitazawa, S., Miyake, H., Kamidono, S., and Nakajima, M. Serum matrix metallo-proteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int. J. Cancer, 79: 96-101, 1998.
20. Schalken, J. A. New perspectives in the treatment of prostate cancer. Eur. Urol., 31(Suppl. 2): 20-23, 1997.
21. Tlsty, T. D. Cell-adhesion-dependent influences on genomic instability and carcinogenesis. Curr. Opin. Cell Biol., 10: 647-653, 1998.
22. Ilyas, M., and Tomlinson, I. P. M. The interactions of APC, E-cadherin and β-catenin in tumor development and progression. J. Pathol., 182: 128-137, 1997.
23. Nakamura, Y. Cleaning up on β-catenin. Nat. Med., 3: 499-500, 1997.